Literature DB >> 27198500

Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Y Dong1,2, F Liu3, C Wu1,2, S Li1,2, X Zhao1,2, P Zhang1,2, J Jiao1,2, X Yu1,2, Y Ji1,2, M Zhang4.   

Abstract

Breakpoint cluster region-Abelson murine leukaemia viral oncogene homologue 1 (BCR-ABL1), encoded by the Philadelphia (Ph) chromosome, is the characteristic of chronic myeloid leukaemia (CML) and a subset of acute lymphoblastic leukaemia (ALL). We demonstrated that expression of the Ik6 transcript, which lacked exons 3-6, was observed exclusively in BCR-ABL1(+) B ALL and lymphoid blast crisis CML (BC-CML) patients harbouring the IKZF1 Δ3-6 deletion. To confirm the hypothesis that illegitimate recombination activating gene protein (RAG)-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia, we first demonstrated that the expression rates of RAG1 and RAG2, collectively called RAG, were higher in ALL and BC-CML (lymphoid). Notably, analysis of relationships among RAG, BCR-ABL1 and Ikaros 6 (Ik6) showed that Ik6 can be generated only if RAG and BCR-ABL1 are co-existing. The sequencing data showed that the deleted segments of introns 2 and 6 contained cryptic recombination signal sequences (cRSSs) and frequently had non-template nucleotides inserted between breakpoints. Furthermore, we used chromatin immunoprecipitation (ChIP) technology and demonstrated that the sequences directly flanking IKZF1 Δ3-6 deletion breakpoints have significantly higher levels of histone H3 lysine 4 trimethylation (H3K4me3) modifications. Overall, RAG expression, good-quality cRSS and a specific chromatin modification, H3K4me3, satisfy the conditions of RAG's off-target effects on IKZF1. Our work provides evidence for RAG-mediated IKZF1 Δ3-6 deletion. Our results raise the prospect that RAG is a valuable biomarker in disease surveillance. Dissecting the contribution of RAG should not only provide valuable mechanistic insights, but will also lead to a new therapeutic direction.
© 2016 British Society for Immunology.

Entities:  

Keywords:  ALL; BCR-ABL1; CML; Ik6; RAG

Mesh:

Substances:

Year:  2016        PMID: 27198500      PMCID: PMC4991516          DOI: 10.1111/cei.12812

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  V(D)J recombination: mechanisms of initiation.

Authors:  David G Schatz; Patrick C Swanson
Journal:  Annu Rev Genet       Date:  2011-08-19       Impact factor: 16.830

2.  Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation.

Authors:  L Wang; A Howarth; R E Clark
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

Review 3.  Recombination centres and the orchestration of V(D)J recombination.

Authors:  David G Schatz; Yanhong Ji
Journal:  Nat Rev Immunol       Date:  2011-03-11       Impact factor: 53.106

Review 4.  Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 5.  Chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet       Date:  2014-12-05       Impact factor: 79.321

Review 6.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

Review 7.  Acute lymphoblastic leukemia.

Authors:  Mihaela Onciu
Journal:  Hematol Oncol Clin North Am       Date:  2009-08       Impact factor: 3.722

8.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

9.  An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.

Authors:  E Clappier; M F Auclerc; J Rapion; M Bakkus; A Caye; A Khemiri; C Giroux; L Hernandez; E Kabongo; S Savola; T Leblanc; K Yakouben; G Plat; V Costa; A Ferster; S Girard; O Fenneteau; J M Cayuela; F Sigaux; N Dastugue; S Suciu; Y Benoit; Y Bertrand; J Soulier; H Cavé
Journal:  Leukemia       Date:  2013-09-25       Impact factor: 11.528

Review 10.  Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Kathrin M Bernt; Stephen P Hunger
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

View more
  7 in total

1.  Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia.

Authors:  Daniel W Thomson; Nur Hezrin Shahrin; Paul P S Wang; Carol Wadham; Naranie Shanmuganathan; Hamish S Scott; Marcel E Dinger; Timothy P Hughes; Andreas W Schreiber; Susan Branford
Journal:  Leukemia       Date:  2020-02-19       Impact factor: 11.528

2.  RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.

Authors:  Meng Yuan; Yang Wang; Mengting Qin; Xiaohui Zhao; Xiaodong Chen; Dandan Li; Yinsha Miao; Wood Otieno Odhiambo; Huasheng Liu; Yunfeng Ma; Yanhong Ji
Journal:  Cancer Sci       Date:  2021-05-18       Impact factor: 6.716

Review 3.  The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.

Authors:  Szymon Janczar; Karolina Janczar; Agata Pastorczak; Hani Harb; Adam J W Paige; Beata Zalewska-Szewczyk; Marian Danilewicz; Wojciech Mlynarski
Journal:  Cancers (Basel)       Date:  2017-01-03       Impact factor: 6.639

4.  Identification and characterization of a murine model of BCR‑ABL1+ acute B‑lymphoblastic leukemia with central nervous system metastasis.

Authors:  Xiaozhuo Yu; Hua Zhang; Meng Yuan; Ping Zhang; Yang Wang; Mingzhe Zheng; Zhuangwei Lv; Woodvine Otieno Odhiambo; Canyu Li; Chengcheng Liu; Yunfeng Ma; Yanhong Ji
Journal:  Oncol Rep       Date:  2019-06-03       Impact factor: 3.906

Review 5.  The ESC: The Dangerous By-Product of V(D)J Recombination.

Authors:  Alastair L Smith; James N F Scott; Joan Boyes
Journal:  Front Immunol       Date:  2019-07-04       Impact factor: 7.561

Review 6.  Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.

Authors:  Lukasz Komorowski; Klaudyna Fidyt; Elżbieta Patkowska; Malgorzata Firczuk
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

7.  RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.

Authors:  Matti Kankainen; Satu Mustjoki; Shady Adnan Awad; Olli Dufva; Aleksandr Ianevski; Bishwa Ghimire; Jan Koski; Pilvi Maliniemi; Daniel Thomson; Andreas Schreiber; Caroline A Heckman; Perttu Koskenvesa; Matti Korhonen; Kimmo Porkka; Susan Branford; Tero Aittokallio
Journal:  Leukemia       Date:  2020-08-11       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.